Source:http://linkedlifedata.com/resource/pubmed/id/19620476
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
24
|
| pubmed:dateCreated |
2009-8-19
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
1527-7755
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:day |
20
|
| pubmed:volume |
27
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
e70; author reply e71
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:19620476-Antineoplastic Agents,
pubmed-meshheading:19620476-Humans,
pubmed-meshheading:19620476-Interferon-alpha,
pubmed-meshheading:19620476-Melanoma,
pubmed-meshheading:19620476-Quality of Life,
pubmed-meshheading:19620476-Recombinant Proteins,
pubmed-meshheading:19620476-Skin Neoplasms
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
Quality of life in patients receiving high-dose interferon alfa-2b after resected high-risk melanoma.
|
| pubmed:publicationType |
Letter,
Comment
|